BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aratana Therapeutics Announces Full Exercise of Over-Allotment Option


7/15/2013 10:07:17 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

KANSAS CITY, Kan. and BOSTON, July 11, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, today announced the full exercise of the over-allotment option granted to the underwriters to purchase 862,500 additional shares of common stock, at a public offering price of $6.00 per share, in connection with its previously announced initial public offering of 5,750,000 shares of common stock that closed on July 2, 2013, bringing the total gross proceeds from the offering to $39,675,000, before deducting the underwriting discounts and commissions and other offering expenses payable by Aratana Therapeutics. The company's common stock is listed on The NASDAQ Global Market under the trading symbol "PETX."

Stifel and Lazard Capital Markets acted as lead book-running managers for the offering. William Blair, JMP Securities and Craig-Hallum Capital Group acted as co-managers.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 26, 2013. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; or from Lazard Capital Markets LLC, Attn: Syndicate Department, 30 Rockefeller Plaza, 48th Floor, New York, NY 10020, or by calling (800) 542-0970.

Contacts:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D./Andrew Mielach
jdrumm@tiberend.com; (212) 375-2664
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES